atenolol has been researched along with Cardiovascular Stroke in 212 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations." | 9.19 | Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. ( Abraham, TN; Agarwal, R; Pappas, MK; Sinha, AD; Tegegne, GG, 2014) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 9.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 9.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 9.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "The purpose of the study was to evaluate the influence of atenolol, a selective, beta1-adrenoblocker, on the quality of life (QL) of patients with old myocardial infarction (MI)." | 9.12 | [Quality of life of patients with old myocardial infarction on prolonged therapy with atenolol]. ( Kaliuzhin, VV; Kaliuzhina, EV; Maleeva, MA; Pushnikova, EIu; Solovtsev, MA; Tepliakov, AT, 2006) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 9.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 9.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "In a single-centre, randomized, open, endpoint-blinded, parallel group study, 232 patients with acute myocardial infarction were randomized to treatment with carvedilol or atenolol." | 9.11 | A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. ( Abdelnoor, M; Jonsson, G; Kjeldsen, SE; Müller, C; Os, I; Westheim, A, 2005) |
| "To evaluate effects of carvedilol (Akridilol, AKRIKHIN, Russia) on central hemodynamics, microvascular bed, hemorheology, von Willebrand factor (VWF) activity, clinical efficacy of the drug and influence on exercise tolerance in patients with Q myocardial infarction (QMI) compared to therapy with atenolol." | 9.11 | [Carvedilol in combined therapy of patients with Q myocardial infarction]. ( Iakovleva, MS; Mironova, MA; Sadionchenko, VS; Shekhian, GG, 2005) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "To study effects of atenolol and trimetazidine on heart rhythm variability in postmyocardial infarction patients with moderate left ventricular dysfunction." | 9.10 | [Effect of atenolol and trimetazidine on dispersion of cardiac rhythm in patients with moderately expressed postinfarction left ventricular dysfunction]. ( Kaliuzhin, VV; Kamaev, DIu; Solovtsov, MA; Tepliakov, AT, 2002) |
| "The Carvedilol Acute Myocardial Infarction Study (CAMIS) investigates cardiac remodeling in patients (n = 250) randomized to carvedilol vs atenolol and treated for 12 months after acute myocardial infarction." | 9.10 | Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. ( Eide, I; Fossum, E; Høieggen, A; Jonsson, G; Kjeldsen, SE; Os, I; Westheim, A, 2002) |
| "To assess antiischemic efficacy, safety and effect on myocardial perfusion of a course treatment with mildronate (as monotherapy and in combination with atenolol) in patients with postinfarction left ventricular dysfunction associated with moderate heart failure." | 9.10 | [The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction]. ( Mamchur, SE; Sankevitch, TV; Stepatcheva, TA; Teplyakov, AT, 2003) |
| "The acute hemodynamic effects of 20 mg iv amlodipine were evaluated in a placebo-controlled study in 16 normotensive patients 15 +/- 1 days after an acute myocardial infarction by covariance analysis." | 9.08 | Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol. ( Baron, B; Bernaud, C; Hotton, JM; Kahn, JC; Marchand, X; Pathé, M; Rocha, P; Zannier, D, 1997) |
| "To investigate the actions of beta-blocker (atenolol) and ACE inhibitor (enalapril) for the secondary prevention of the main cardiac complications after acute myocardial infarction (AMI)." | 9.08 | Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. Beijing Collaborative Study Group. ( Fan, Z; Wu, N, 1997) |
| "Although atenolol appears to improve outcomes after thrombolysis for myocardial infarction, early intravenous atenolol seems of limited value." | 9.08 | Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. ( Armstrong, PW; Brener, SJ; Califf, RM; Cox, JL; Granger, CB; Lee, KL; Naylor, CD; Pfisterer, M; Stebbins, AL; Topol, EJ; van de Werf, F, 1998) |
| "In order to dissociate the Class III effects of sotalol on QT interval and arrhythmias from those of chronic beta-receptor blockade, we compared the effects of sotalol 160 mg b." | 9.06 | A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. ( Alexopoulos, D; Cobbe, PC; Cobbe, SM; Johnston, J; McCaie, CP; Winner, SJ, 1988) |
| "0 h after the onset of suspected acute myocardial infarction were randomised either to a control group or to a group receiving atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days)." | 9.06 | Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. ( , 1986) |
| "Plasma atrial natriuretic peptide (ANP) was measured during dynamic exercise in 10 patients with coronary heart disease before and after single dose atenolol 50 mg and acebutolol 200 mg, respectively." | 9.06 | Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol. ( Keller, N; Larsen, J; Storm, T; Sykulski, R; Thamsborg, G, 1988) |
| "10 mg/kg) and oral (50 and 100 mg) atenolol were compared in a randomized between-group study of 24 men within seventeen hours of an acute uncomplicated myocardial infarction; 6 subjects were evaluated in each of the four groups." | 9.06 | Circulatory effects of intravenous and oral atenolol in acute myocardial infarction. ( Hafizullah, M; Midtbø, K; Reynolds, GW; Silke, B; Taylor, SH; Verma, SP, 1988) |
| "A randomised, double-blind, placebo controlled study of morbidity and mortality was carried out using heparin, atenolol, and a combination of both drugs, in 214 patients with the intermediate coronary syndrome." | 9.05 | Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. ( Telford, AM; Wilson, C, 1981) |
| "The value of beta-blockade and of disopyramide phosphate in the immediate treatment of patients with suspected acute myocardial infarction was assessed in two placebo controlled trials." | 9.05 | Acute intervention studies in patients with myocardial infarction using atenolol, propranolol, oxprenolol and disopyramide phosphate. ( Wilcox, RG, 1981) |
| "Pain relief in acute myocardial infarction (AMI) by the beta-adrenoceptor antagonist, atenolol, was demonstrated by three separate studies." | 9.05 | Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. ( Bennett, DH; Bray, CL; Cruickshank, JM; Faragher, EB; Ramsdale, DR; Sleight, P; Ward, C; Yusuf, S, 1982) |
| "The effect of intravenous atenolol on ventricular arrhythmias in acute myocardial infarction was assessed in 182 patients admitted within 12 hours of the onset of chest pain." | 9.05 | Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. ( Furze, L; Ramsdale, D; Rossi, PR; Sleight, P; Yusuf, S, 1983) |
| "The value of beta-blockade for suspected acute myocardial infarction was assessed by determining the six-week and one-year mortality rates in patients started on propranolol, atenolol, or placebo immediately on entry to a coronary care unit." | 9.05 | Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. ( Banks, DC; Hampton, JR; Mitchell, JR; Roland, JM; Wilcox, RG, 1980) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "Metoprolol exerts a disruptive action on neutrophil dynamics during exacerbated inflammation, resulting in an infarct-limiting effect not observed with atenolol or propranolol." | 7.96 | Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation. ( Clemente-Moragón, A; Fuster, V; García-Prieto, J; Gómez, M; Ibáñez, B; Lalama, DV; Martínez, F; Oliver, E; Sánchez-Cabo, F; Villena-Gutiérrez, R, 2020) |
| "We compared the effects of heart rate reduction (HRR) by the hyperpolarization-activated pacemaker current (I(f)) channel inhibitor ivabradine (MI+Iva) and the beta(1)-blocker atenolol (MI+Aten) on ventricular remodeling and perfusion after myocardial infarction (MI) in middle-aged (12 mo) Sprague-Dawley rats." | 7.75 | Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy. ( Campanelli, JJ; Christensen, LP; Dedkov, EI; Tomanek, RJ; Weiss, RM; Zhang, RL; Zheng, W, 2009) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 7.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 7.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "To compare the beneficial effects of Atenolol and Metoprolol on cardiomyocyte apoptosis and related gene expressions after acute myocardial infarction (AMI) in rats." | 7.73 | [Effects of atenolol and metoprolol on cardiomyocyte apoptosis and related gene expression after acute myocardial infarction in rats]. ( Chen, JL; Chen, X; Chen, YF; Chen, ZJ; Gao, RL; Ruan, YM; Si, WX; Sun, RC; Tian, Y; Wang, QZ; Yang, YJ; Zhou, YW, 2006) |
| " One example of the latter is the use of intravenous atenolol in acute myocardial infarction where, despite a large trial clearly demonstrating that immediate therapy is relatively safe in patients with acute myocardial infarction and reduces in-hospital mortality, its routine use remains extremely variable." | 7.69 | What happened to intravenous atenolol in acute myocardial infarction? ( Sleight, P, 1994) |
| "This study analyzed, with spectral techniques, the effects of atenolol or metoprolol on RR interval variability in 20 patients 4 weeks after the first uncomplicated myocardial infarction." | 7.69 | Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. ( La Rovere, MT; Lombardi, F; Malliani, A; Mortara, A; Sandrone, G; Torzillo, D, 1994) |
| "The aim of this study was to assess the hemodynamic response to intravenous atenolol in elderly patients with acute myocardial infarction." | 7.68 | Intravenous atenolol in elderly patients in the early phase of acute myocardial infarction. ( Apostolou, T; Karavolias, G; Kremastinos, D; Kyriakides, ZS; Papadopoulos, C; Paraskevaidis, J; Toutouzas, P, 1992) |
| "One hundred thirty-one patients presenting with acute myocardial infarction (AMI) a mean of 3 hours after the onset of symptoms were treated with oral aspirin and intravenous thrombolytic therapy followed by heparin." | 7.68 | Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction. ( Commerford, PJ; Gordon, GD; Green, BK; Horak, AR; Millar, RN, 1992) |
| ") and oral dose regimen of atenolol was evaluated in 21 patients with acute myocardial infarction (MI)." | 7.68 | Pharmacokinetic and pharmacodynamic properties of atenolol in acute myocardial infarction. ( Held, P; Regårdh, CG; Swedberg, K, 1990) |
| "Nine hundred and thirty-nine patients with moderate to severe hypertension, observed for up to 10 years, were found to benefit from treatment with the beta1-selective agent atenolol (Tenormin), usually coprescribed with diuretics with or without vasodilators or other agents." | 7.68 | Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol). ( Cruickshank, JM, 1990) |
| "In the last year, two large randomized controlled trials of metoprolol (MIAMI, almost 6,000 patients) and atenolol (ISIS 1, over 16,000 patients) given intravenously within 12 hours of the onset of acute myocardial infarction reduced mortality by about 15% in low-risk subjects." | 6.15 | Use of beta adrenoceptor blockade during and after acute myocardial infarction. ( Sleight, P, 1986) |
| "Pirenzepine is an atropine analogue approved to treat peptic ulcer disease in Europe that is devoid of central actions, which are mostly responsible for anti-muscarinic agents side effects." | 5.32 | Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade. ( Adamson, PB; Foreman, RD; Pedretti, RF; Prete, G; Vanoli, E, 2003) |
| "Atenolol-treated MI rats had a significantly higher LVEDP, RAP and LVEDVI than did rats with untreated MI." | 5.29 | Effect of prolonged beta-adrenergic blockade induced by atenolol on left ventricular remodeling after acute myocardial infarction in the rat. ( Kawarabayashi, T; Nishikimi, T; Shimada, K; Takeda, T; Takeuchi, K, 1995) |
| "The greater sensitivity of phase 1a arrhythmias to beta-blockade and the lack of a decrease in ventricular fibrillation threshold during phase 1b might indicate differences in the genesis of arrhythmias and fibrillation in phases 1a and 1b." | 5.26 | Prophylaxis of ventricular fibrillation after acute experimental coronary occlusion by chronic beta-adrenoceptor blockade with atenolol. ( Bucher, P; Meesmann, W; Menken, U; Wiegand, V, 1979) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke." | 5.20 | Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. ( Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2015) |
| "Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations." | 5.19 | Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. ( Abraham, TN; Agarwal, R; Pappas, MK; Sinha, AD; Tegegne, GG, 2014) |
| "8 years of randomized losartan-based or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.15 | In-treatment stroke volume predicts cardiovascular risk in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K, 2011) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 5.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 5.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| "To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden." | 5.13 | Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 5.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "The purpose of the study was to evaluate the influence of atenolol, a selective, beta1-adrenoblocker, on the quality of life (QL) of patients with old myocardial infarction (MI)." | 5.12 | [Quality of life of patients with old myocardial infarction on prolonged therapy with atenolol]. ( Kaliuzhin, VV; Kaliuzhina, EV; Maleeva, MA; Pushnikova, EIu; Solovtsev, MA; Tepliakov, AT, 2006) |
| "Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.12 | The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. ( Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA, 2007) |
| "The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 5.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "In a single-centre, randomized, open, endpoint-blinded, parallel group study, 232 patients with acute myocardial infarction were randomized to treatment with carvedilol or atenolol." | 5.11 | A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. ( Abdelnoor, M; Jonsson, G; Kjeldsen, SE; Müller, C; Os, I; Westheim, A, 2005) |
| "To evaluate effects of carvedilol (Akridilol, AKRIKHIN, Russia) on central hemodynamics, microvascular bed, hemorheology, von Willebrand factor (VWF) activity, clinical efficacy of the drug and influence on exercise tolerance in patients with Q myocardial infarction (QMI) compared to therapy with atenolol." | 5.11 | [Carvedilol in combined therapy of patients with Q myocardial infarction]. ( Iakovleva, MS; Mironova, MA; Sadionchenko, VS; Shekhian, GG, 2005) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "To study effects of atenolol and trimetazidine on heart rhythm variability in postmyocardial infarction patients with moderate left ventricular dysfunction." | 5.10 | [Effect of atenolol and trimetazidine on dispersion of cardiac rhythm in patients with moderately expressed postinfarction left ventricular dysfunction]. ( Kaliuzhin, VV; Kamaev, DIu; Solovtsov, MA; Tepliakov, AT, 2002) |
| "The Carvedilol Acute Myocardial Infarction Study (CAMIS) investigates cardiac remodeling in patients (n = 250) randomized to carvedilol vs atenolol and treated for 12 months after acute myocardial infarction." | 5.10 | Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. ( Eide, I; Fossum, E; Høieggen, A; Jonsson, G; Kjeldsen, SE; Os, I; Westheim, A, 2002) |
| "To assess antiischemic efficacy, safety and effect on myocardial perfusion of a course treatment with mildronate (as monotherapy and in combination with atenolol) in patients with postinfarction left ventricular dysfunction associated with moderate heart failure." | 5.10 | [The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction]. ( Mamchur, SE; Sankevitch, TV; Stepatcheva, TA; Teplyakov, AT, 2003) |
| "The acute hemodynamic effects of 20 mg iv amlodipine were evaluated in a placebo-controlled study in 16 normotensive patients 15 +/- 1 days after an acute myocardial infarction by covariance analysis." | 5.08 | Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol. ( Baron, B; Bernaud, C; Hotton, JM; Kahn, JC; Marchand, X; Pathé, M; Rocha, P; Zannier, D, 1997) |
| "In older persons with isolated systolic hypertension, stepped-care treatment based on low-dose chlorthalidone exerted a strong protective effect in preventing heart failure." | 5.08 | Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. ( Applegate, WB; Berge, KG; Berkson, DM; Black, HR; Blaufox, MD; Cohen, JD; Curb, JD; Cutler, J; Davis, BR; Grimm, RH; Kostis, JB; Lacy, CR; McDonald, R; Perry, HM; Schron, E; Smith, WM; Wassertheil-Smoller, S, 1997) |
| "To investigate the actions of beta-blocker (atenolol) and ACE inhibitor (enalapril) for the secondary prevention of the main cardiac complications after acute myocardial infarction (AMI)." | 5.08 | Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. Beijing Collaborative Study Group. ( Fan, Z; Wu, N, 1997) |
| "Although atenolol appears to improve outcomes after thrombolysis for myocardial infarction, early intravenous atenolol seems of limited value." | 5.08 | Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. ( Armstrong, PW; Brener, SJ; Califf, RM; Cox, JL; Granger, CB; Lee, KL; Naylor, CD; Pfisterer, M; Stebbins, AL; Topol, EJ; van de Werf, F, 1998) |
| "In a double-blind study, we examined the effects of early intravenous and continued oral administration of a beta-blocker (atenolol), a specific bradycardiac agent (alinidine) or placebo on left ventricular function, late coronary artery patency, infarct size, exercise capacity and incidence of arrhythmias." | 5.07 | Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. ( Brzostek, T; Collen, D; Heidbüchel, H; Janssens, L; Lesaffre, E; Mortelmans, L; Scheys, I; Van de Werf, F; Wackers, FJ; Willems, GM, 1993) |
| "The aim of the study was to assess the effects of gallopamil and atenolol administration on left ventricular (LV) relaxation and filling in patients (pts) with acute myocardial infarction (AMI), by pulsed Doppler echocardiography (PDE)." | 5.07 | [Pharmacological effects on left diastolic ventricular function in acute myocardial infarct: comparison of gallopamil and atenolol]. ( Milazzotto, F; Natale, E; Ricci, R; Tubaro, M, 1991) |
| "In order to dissociate the Class III effects of sotalol on QT interval and arrhythmias from those of chronic beta-receptor blockade, we compared the effects of sotalol 160 mg b." | 5.06 | A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. ( Alexopoulos, D; Cobbe, PC; Cobbe, SM; Johnston, J; McCaie, CP; Winner, SJ, 1988) |
| "0 h after the onset of suspected acute myocardial infarction were randomised either to a control group or to a group receiving atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days)." | 5.06 | Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. ( , 1986) |
| "In a large randomised trial of early beta-blockade in acute myocardial infarction (ISIS-1), almost all the reduction in mortality associated with the use of atenolol occurred on the day of admission or on the subsequent day." | 5.06 | Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. ( , 1988) |
| "Plasma atrial natriuretic peptide (ANP) was measured during dynamic exercise in 10 patients with coronary heart disease before and after single dose atenolol 50 mg and acebutolol 200 mg, respectively." | 5.06 | Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol. ( Keller, N; Larsen, J; Storm, T; Sykulski, R; Thamsborg, G, 1988) |
| "10 mg/kg) and oral (50 and 100 mg) atenolol were compared in a randomized between-group study of 24 men within seventeen hours of an acute uncomplicated myocardial infarction; 6 subjects were evaluated in each of the four groups." | 5.06 | Circulatory effects of intravenous and oral atenolol in acute myocardial infarction. ( Hafizullah, M; Midtbø, K; Reynolds, GW; Silke, B; Taylor, SH; Verma, SP, 1988) |
| " All patients were treated in the same hypertension clinic with the beta 1-selective agent atenolol, administered either alone or more usually with a diuretic with or without a vasodilator or other agents." | 5.06 | Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives. ( Cruickshank, JM; Pennert, K; Sörman, AE; Thorp, JM; Zacharias, FJ; Zacharias, FM, 1987) |
| "A randomised, double-blind, placebo controlled study of morbidity and mortality was carried out using heparin, atenolol, and a combination of both drugs, in 214 patients with the intermediate coronary syndrome." | 5.05 | Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. ( Telford, AM; Wilson, C, 1981) |
| "The value of beta-blockade and of disopyramide phosphate in the immediate treatment of patients with suspected acute myocardial infarction was assessed in two placebo controlled trials." | 5.05 | Acute intervention studies in patients with myocardial infarction using atenolol, propranolol, oxprenolol and disopyramide phosphate. ( Wilcox, RG, 1981) |
| "Pain relief in acute myocardial infarction (AMI) by the beta-adrenoceptor antagonist, atenolol, was demonstrated by three separate studies." | 5.05 | Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. ( Bennett, DH; Bray, CL; Cruickshank, JM; Faragher, EB; Ramsdale, DR; Sleight, P; Ward, C; Yusuf, S, 1982) |
| "The effect of intravenous atenolol on ventricular arrhythmias in acute myocardial infarction was assessed in 182 patients admitted within 12 hours of the onset of chest pain." | 5.05 | Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. ( Furze, L; Ramsdale, D; Rossi, PR; Sleight, P; Yusuf, S, 1983) |
| "The value of beta-blockade for suspected acute myocardial infarction was assessed by determining the six-week and one-year mortality rates in patients started on propranolol, atenolol, or placebo immediately on entry to a coronary care unit." | 5.05 | Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. ( Banks, DC; Hampton, JR; Mitchell, JR; Roland, JM; Wilcox, RG, 1980) |
| "Twenty-four-hour electrocardiographic tape-recording was used to investigate the incidence of arrhythmias in patients with suspected myocardial infarction who were receiving either propranolol, atenolol, or placebo." | 5.04 | Effect of beta-blockers on arrhythmias during six weeks after suspected myocardial infarction. ( Banks, DC; Edwards, B; Fentem, PH; Hampton, JR; Roland, JM; Wilcox, RG, 1979) |
| "Because carvedilol is a unique vasodilating β blocker (BB) exerting antioxidant activity and pleiotropic effects, it was theorized that it may confer more potent beneficial effects on cardiovascular mortality and morbidity in acute myocardial infarction (AMI) and heart failure (HF) settings." | 4.89 | Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). ( DiNicolantonio, JJ; Fares, H; Lavie, CJ; Menezes, AR; O'Keefe, JH, 2013) |
| " We also now have another bradycardic agent, ivabradine, which may prove very useful in heart failure patients who cannot tolerate a betablocker." | 4.84 | [What are the alternatives to betablockers in 2009?]. ( van de Borne, P, 2008) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| "Amlodipine lowered long-term gout risk compared with lisinopril or chlorthalidone." | 3.96 | The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Beach, JL; Davis, BR; Ishak, A; Juraschek, SP; Mukamal, KJ; Shmerling, RH; Simpson, LM, 2020) |
| "Metoprolol exerts a disruptive action on neutrophil dynamics during exacerbated inflammation, resulting in an infarct-limiting effect not observed with atenolol or propranolol." | 3.96 | Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation. ( Clemente-Moragón, A; Fuster, V; García-Prieto, J; Gómez, M; Ibáñez, B; Lalama, DV; Martínez, F; Oliver, E; Sánchez-Cabo, F; Villena-Gutiérrez, R, 2020) |
| " Three weeks after inducing myocardial infarction (MI), rats were treated daily with or without 20 and 75 mg/kg atenolol, a selective β(1) -AR antagonist, or propranolol, a non-selective β-AR antagonist, for 5 weeks." | 3.77 | β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure. ( Dhalla, NS; Elimban, V; Machackova, J; Sanganalmath, SK, 2011) |
| "Chronic heart rate reduction (HRR) therapy following myocardial infarction, using either the pure HRR agent ivabradine or the beta-blocker atenolol, has been shown to preserve maximal coronary perfusion, via reduction of perivascular collagen and a decrease in renin-angiotensin system activation." | 3.76 | Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction. ( Christensen, LP; Tomanek, RJ; Zhang, RL, 2010) |
| "We compared the effects of heart rate reduction (HRR) by the hyperpolarization-activated pacemaker current (I(f)) channel inhibitor ivabradine (MI+Iva) and the beta(1)-blocker atenolol (MI+Aten) on ventricular remodeling and perfusion after myocardial infarction (MI) in middle-aged (12 mo) Sprague-Dawley rats." | 3.75 | Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy. ( Campanelli, JJ; Christensen, LP; Dedkov, EI; Tomanek, RJ; Weiss, RM; Zhang, RL; Zheng, W, 2009) |
| " Published comparisons of the beta-adrenergic blocker atenolol and non-atenolol beta-adrenergic blockers indicate different effects on death rates, arrhythmias, peripheral vascular resistance and prognosis post myocardial infarction, all in disfavor of atenolol." | 3.74 | Does atenolol differ from other beta-adrenergic blockers? ( Aursnes, I; Gåsemyr, J; Natvig, B; Osnes, JB; Tvete, IF, 2007) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 3.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 3.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "To compare the beneficial effects of Atenolol and Metoprolol on cardiomyocyte apoptosis and related gene expressions after acute myocardial infarction (AMI) in rats." | 3.73 | [Effects of atenolol and metoprolol on cardiomyocyte apoptosis and related gene expression after acute myocardial infarction in rats]. ( Chen, JL; Chen, X; Chen, YF; Chen, ZJ; Gao, RL; Ruan, YM; Si, WX; Sun, RC; Tian, Y; Wang, QZ; Yang, YJ; Zhou, YW, 2006) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| " At similar blood pressure control, losartan, as compared to atenolol, reduced the relative risk of primary cardiovascular event (death, myocardial infarction, or stroke) by 13% (p = 0." | 3.71 | [Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan]. ( Scheen, AJ, 2002) |
| " Of 10,991 myocardial infarction survivors dispensed atenolol, metoprolol, propranolol, or timolol, 9458 (86." | 3.70 | Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. ( Anderson, GM; Clark, JP; Gurwitz, JH; Lau, P; Rochon, PA; Shear, NH; Tu, JV, 1999) |
| "To study a relationship between reduced heart rate variability and ventricular ectopic activity in patients with coronary artery disease and also efficiency of atenolol in suppression of ventricular arrhythmias and increase of heart rate variability." | 3.70 | [Depression of diurnal dispersion of sinus rhythm in patients after myocardial infarct]. ( Kaliuzhin, VV; Maleeva, MA; Pushnikova, EIu; Solovtsov, MA; Tepliakov, AT, 2000) |
| " One example of the latter is the use of intravenous atenolol in acute myocardial infarction where, despite a large trial clearly demonstrating that immediate therapy is relatively safe in patients with acute myocardial infarction and reduces in-hospital mortality, its routine use remains extremely variable." | 3.69 | What happened to intravenous atenolol in acute myocardial infarction? ( Sleight, P, 1994) |
| " During ischemia alone, the incidence of ventricular fibrillation in animals who underwent all phases of the study was 6 of 9; with atenolol (0." | 3.69 | Anti-arrhythmic efficacy of beta-adrenergic blockade during acute ischemia in myocardium with scar. ( Fusilli, L; Lee, W; Patel, J; Regan, TJ, 1994) |
| "This study analyzed, with spectral techniques, the effects of atenolol or metoprolol on RR interval variability in 20 patients 4 weeks after the first uncomplicated myocardial infarction." | 3.69 | Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. ( La Rovere, MT; Lombardi, F; Malliani, A; Mortara, A; Sandrone, G; Torzillo, D, 1994) |
| "The aim of this study was to assess the hemodynamic response to intravenous atenolol in elderly patients with acute myocardial infarction." | 3.68 | Intravenous atenolol in elderly patients in the early phase of acute myocardial infarction. ( Apostolou, T; Karavolias, G; Kremastinos, D; Kyriakides, ZS; Papadopoulos, C; Paraskevaidis, J; Toutouzas, P, 1992) |
| "One hundred thirty-one patients presenting with acute myocardial infarction (AMI) a mean of 3 hours after the onset of symptoms were treated with oral aspirin and intravenous thrombolytic therapy followed by heparin." | 3.68 | Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction. ( Commerford, PJ; Gordon, GD; Green, BK; Horak, AR; Millar, RN, 1992) |
| ") and oral dose regimen of atenolol was evaluated in 21 patients with acute myocardial infarction (MI)." | 3.68 | Pharmacokinetic and pharmacodynamic properties of atenolol in acute myocardial infarction. ( Held, P; Regårdh, CG; Swedberg, K, 1990) |
| "Nine hundred and thirty-nine patients with moderate to severe hypertension, observed for up to 10 years, were found to benefit from treatment with the beta1-selective agent atenolol (Tenormin), usually coprescribed with diuretics with or without vasodilators or other agents." | 3.68 | Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol). ( Cruickshank, JM, 1990) |
| "In patients with mild hypertension, flurbiprofen in a dose of 100 mg daily for 7 days attenuated the hypotensive effect of a single dose of propranolol 80 mg but not of atenolol 100 mg." | 3.67 | Flurbiprofen interaction with single doses of atenolol and propranolol. ( Hawksworth, GM; McLean, I; Petrie, JC; Webster, J, 1984) |
| "To investigate whether the lower the blood pressure (BP) the better the prognosis for the patient with moderate-to-severe hypertension, an assessment was made of 902 patients who received the beta 1-selective beta-blocker atenolol (median dose 100 mg a day), either alone or with other antihypertensive agents, for up to 10 years (mean 6." | 3.67 | Benefits and potential harm of lowering high blood pressure. ( Cruickshank, JM; Thorp, JM; Zacharias, FJ, 1987) |
| "Cardiac functions like heart size, heart rate, and blood pressure were studied at rest in 23 digitalized and 24 not digitalized patinents recovering from a myocardial infarction, in 16 patients with arterial hypertension and in 9 patients with regulatory dysfunctions of the circulation before and after a three week period of treatment with 2 x 50 mg or 2 x 100 mg atenolol per day." | 3.66 | [The effects of atenolol on the heart size, on the heart rate, and on the blood pressure at rest (author's transl)]. ( Frisch, P, 1978) |
| "In animals without myocardial infarction the new beta-sympathicolytic agent atenolol (4-[2'-hydroxy-3'-iso-propylaminopropoxy]-phenyl acetamide, ICI 66 082) dose-dependently decreased heart rate, systolic aortic pressure and cardiac output." | 3.65 | [The effect of atenolol on contractility and hemodynamics of the infarcted heart in comparison to propranolol and practolol (author's transl)]. ( Bischoff, KO; Diesch, J; Geigenmüller, L; Hübner, H; Meesmann, W; Stephan, K, 1975) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "Carvedilol is a direct inhibitor of vascular smooth muscle cell migration and proliferation through inhibition of mitogen-activated protein kinase activity and regulation of cell cycle progression." | 2.71 | Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting. ( Cha, KS; Kim, DI; Kim, DS; Kim, HJ; Kim, JS; Kim, JW; Kim, MH, 2004) |
| "In MI patients left ventricular remodeling is associated with left atrial remodeling." | 2.70 | [Postinfarction remodeling of the left atrium and left ventricle: effects of long-term treatment with beta adrenergic blockers and angiotensin converting enzyme inhibitors]. ( Mazur, NA; Vikent'ev, VV, 2001) |
| "We analyzed the incidence and recurrence rate of early and late primary VF in 9,720 patients with a first acute MI, treated with thrombolytics, enrolled in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 trial." | 2.69 | Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database. ( Cavalli, A; Negri, E; Santoro, L; Volpi, A, 1998) |
| "1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8." | 2.69 | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. ( , 1998) |
| "Captopril and atenolol were equally effective in reducing blood pressure to a mean of 144/83 mm Hg and 143/81 mm Hg respectively, with a similar proportion of patients (27% and 31%) requiring three or more antihypertensive treatments." | 2.69 | Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. ( , 1998) |
| "We investigated prospectively the arrhythmia incidence in 244 patients with AMI receiving alteplase and a double-blind randomized adjunctive therapy with intravenous atenolol, alinidine, or placebo." | 2.67 | Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence. ( Ballet, A; Ector, H; Heidbüchel, H; Tack, J; Van de Werf, F; Vanneste, L, 1994) |
| "Atenolol is an alternative drug in the treatment of PVC in patients with coronary heart disease." | 2.65 | [Atenolol in the treatment of premature ventricular contractions. A double blind study in 68 patients (author's transl)]. ( Brandes, JW; Körst, HA; Lembcke, HJ; Littmann, KP, 1981) |
| "Stroke affects 15 million people per year worldwide." | 2.49 | Beta-blockers for preventing stroke recurrence. ( Atallah, AN; da Silva, EM; De Lima, LG; Saconato, H; Soares, BG, 2013) |
| " In addition, some patients are treated with agents whose long-term use has not been shown to be effective." | 2.43 | Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations. ( Fonarow, GC, 2006) |
| "Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity." | 2.41 | Beta-blockers and diabetes: the bad guys come good. ( Cruickshank, JM, 2002) |
| "Myocardial infarction is rare in pregnancy." | 2.39 | Myocardial infarction in a parturient. A case report with emphasis on medication and management. ( Haring, P; Hietakorpi, S; Koski, E; Nuutinen, LS; Purhonen, S; Söderlin, MK, 1994) |
| "Pirenzepine is an atropine analogue approved to treat peptic ulcer disease in Europe that is devoid of central actions, which are mostly responsible for anti-muscarinic agents side effects." | 1.32 | Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade. ( Adamson, PB; Foreman, RD; Pedretti, RF; Prete, G; Vanoli, E, 2003) |
| "Atenolol was given at a rate of 0." | 1.32 | Intravenous atenolol and esmolol maintain the protective effect of ischemic preconditioning in vivo. ( Andreadou, I; Bofilis, E; Cokkinos, P; Iliodromitis, EK; Kremastinos, DT; Tasouli, A; Zoga, A, 2004) |
| "Myocardial infarction was induced by a 30-min occlusion of a branch of the left coronary artery, followed by 3-h reperfusion." | 1.30 | Hemodynamic changes do not mediate the cardioprotection induced by the A1, adenosine receptor agonist CCPA in the rabbit. ( Casati, C; Forlani, A; Lozza, G; Monopoli, A, 1997) |
| " In the remaining 8 swine, atenolol was infused after 10-min ischemia at a dosage [mean 1." | 1.29 | Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol. ( Heusch, G; Rose, J; Schulz, R; Skyschally, A, 1995) |
| "Atenolol-treated MI rats had a significantly higher LVEDP, RAP and LVEDVI than did rats with untreated MI." | 1.29 | Effect of prolonged beta-adrenergic blockade induced by atenolol on left ventricular remodeling after acute myocardial infarction in the rat. ( Kawarabayashi, T; Nishikimi, T; Shimada, K; Takeda, T; Takeuchi, K, 1995) |
| "The greater sensitivity of phase 1a arrhythmias to beta-blockade and the lack of a decrease in ventricular fibrillation threshold during phase 1b might indicate differences in the genesis of arrhythmias and fibrillation in phases 1a and 1b." | 1.26 | Prophylaxis of ventricular fibrillation after acute experimental coronary occlusion by chronic beta-adrenoceptor blockade with atenolol. ( Bucher, P; Meesmann, W; Menken, U; Wiegand, V, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 65 (30.66) | 18.7374 |
| 1990's | 62 (29.25) | 18.2507 |
| 2000's | 63 (29.72) | 29.6817 |
| 2010's | 20 (9.43) | 24.3611 |
| 2020's | 2 (0.94) | 2.80 |
| Authors | Studies |
|---|---|
| Adebesin, AM | 1 |
| Wesser, T | 1 |
| Vijaykumar, J | 1 |
| Konkel, A | 1 |
| Paudyal, MP | 1 |
| Lossie, J | 1 |
| Zhu, C | 1 |
| Westphal, C | 1 |
| Puli, N | 1 |
| Fischer, R | 1 |
| Schunck, WH | 1 |
| Falck, JR | 1 |
| Juraschek, SP | 1 |
| Simpson, LM | 1 |
| Davis, BR | 3 |
| Shmerling, RH | 1 |
| Beach, JL | 1 |
| Ishak, A | 1 |
| Mukamal, KJ | 1 |
| Clemente-Moragón, A | 1 |
| Gómez, M | 1 |
| Villena-Gutiérrez, R | 1 |
| Lalama, DV | 1 |
| García-Prieto, J | 1 |
| Martínez, F | 1 |
| Sánchez-Cabo, F | 1 |
| Fuster, V | 1 |
| Oliver, E | 1 |
| Ibáñez, B | 1 |
| De Lima, LG | 1 |
| Soares, BG | 1 |
| Saconato, H | 1 |
| Atallah, AN | 1 |
| da Silva, EM | 1 |
| Agarwal, R | 1 |
| Sinha, AD | 1 |
| Pappas, MK | 1 |
| Abraham, TN | 1 |
| Tegegne, GG | 1 |
| Bang, CN | 2 |
| Gerdts, E | 4 |
| Aurigemma, GP | 1 |
| Boman, K | 3 |
| de Simone, G | 1 |
| Dahlöf, B | 15 |
| Køber, L | 2 |
| Wachtell, K | 7 |
| Devereux, RB | 14 |
| Furuichi, Y | 1 |
| Sakamoto, A | 1 |
| DiNicolantonio, JJ | 3 |
| Fuchs, FD | 1 |
| O'Keefe, JH | 2 |
| Vishram, JK | 1 |
| Ibsen, H | 8 |
| Kjeldsen, SE | 13 |
| Lindholm, LH | 6 |
| Mancia, G | 5 |
| Okin, PM | 3 |
| Rothwell, PM | 1 |
| Olsen, MH | 4 |
| Roman, MJ | 1 |
| Palmieri, V | 1 |
| Nieminen, MS | 6 |
| Papademetriou, V | 2 |
| Hille, DA | 4 |
| Oh, PC | 1 |
| Kang, WC | 1 |
| Moon, J | 1 |
| Park, YM | 1 |
| Kim, S | 1 |
| Kim, MG | 1 |
| Lee, K | 1 |
| Ahn, T | 1 |
| Shin, EK | 1 |
| Andersen, SS | 1 |
| Hansen, ML | 1 |
| Gislason, GH | 1 |
| Folke, F | 1 |
| Schramm, TK | 1 |
| Fosbøl, E | 1 |
| Sørensen, R | 1 |
| Rasmussen, S | 1 |
| Abildstrøm, SZ | 1 |
| Madsen, M | 1 |
| Torp-Pedersen, C | 1 |
| Bangalore, S | 2 |
| Messerli, FH | 4 |
| Cohen, JD | 2 |
| Bacher, PH | 1 |
| Sleight, P | 18 |
| Kowey, P | 1 |
| Zhou, Q | 1 |
| Champion, A | 3 |
| Pepine, CJ | 5 |
| van de Borne, P | 1 |
| Shirotani, M | 1 |
| Yokota, R | 1 |
| Kouchi, I | 1 |
| Hirai, T | 1 |
| Uemori, N | 1 |
| Haba, K | 1 |
| Hattori, R | 1 |
| Franklin, SS | 1 |
| Christensen, LP | 3 |
| Zhang, RL | 2 |
| Zheng, W | 1 |
| Campanelli, JJ | 1 |
| Dedkov, EI | 2 |
| Weiss, RM | 2 |
| Tomanek, RJ | 3 |
| Angeli, FS | 1 |
| Shapiro, M | 1 |
| Amabile, N | 1 |
| Orcino, G | 1 |
| Smith, CS | 1 |
| Tacy, T | 1 |
| Boyle, AJ | 1 |
| Chatterjee, K | 1 |
| Glantz, SA | 1 |
| Grossman, W | 1 |
| Yeghiazarians, Y | 1 |
| Machackova, J | 1 |
| Sanganalmath, SK | 1 |
| Elimban, V | 1 |
| Dhalla, NS | 1 |
| Larstorp, AC | 1 |
| van Klei, WA | 1 |
| Peelen, LM | 1 |
| Buhre, WF | 1 |
| Vaughn, DR | 1 |
| Lønnebakken, MT | 1 |
| Hackam, DG | 1 |
| Poirier, L | 1 |
| Lacourcière, Y | 1 |
| Lavie, CJ | 1 |
| Fares, H | 1 |
| Menezes, AR | 1 |
| Julius, S | 6 |
| Aurup, P | 1 |
| Edelman, J | 1 |
| Beevers, G | 5 |
| de Faire, U | 5 |
| Fyhrquist, F | 5 |
| Kristianson, K | 4 |
| Lederballe-Pedersen, O | 5 |
| Omvik, P | 5 |
| Oparil, S | 6 |
| Snapinn, S | 1 |
| Wedel, H | 6 |
| Kaliuzhin, VV | 4 |
| Tepliakov, AT | 5 |
| Kamaev, DIu | 1 |
| Solovtsov, MA | 2 |
| Jonsson, G | 3 |
| Fossum, E | 3 |
| Høieggen, A | 1 |
| Os, I | 4 |
| Eide, I | 1 |
| Westheim, A | 2 |
| Fleming, T | 1 |
| Borer, J | 1 |
| Armstrong, PW | 2 |
| Pfeffer, M | 1 |
| Bossi, M | 1 |
| Tiberti, G | 1 |
| Cruickshank, JM | 7 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Pedretti, RF | 1 |
| Prete, G | 1 |
| Foreman, RD | 2 |
| Adamson, PB | 2 |
| Vanoli, E | 2 |
| Schunkert, H | 1 |
| Teplyakov, AT | 1 |
| Sankevitch, TV | 1 |
| Stepatcheva, TA | 1 |
| Mamchur, SE | 1 |
| Gavrilova, NV | 1 |
| Garganeeva, AA | 1 |
| Cha, KS | 1 |
| Kim, MH | 1 |
| Kim, JW | 1 |
| Kim, DI | 1 |
| Kim, HJ | 1 |
| Kim, DS | 1 |
| Kim, JS | 1 |
| Reims, HM | 2 |
| Brady, WE | 3 |
| Tuxen, C | 1 |
| Bang, LE | 1 |
| Hall, C | 1 |
| Rokkedal, J | 1 |
| Hildebrandt, P | 1 |
| Borch-Johnsen, K | 1 |
| Mogensen, CE | 1 |
| Wan, Y | 1 |
| Iliodromitis, EK | 1 |
| Tasouli, A | 1 |
| Andreadou, I | 1 |
| Bofilis, E | 1 |
| Zoga, A | 1 |
| Cokkinos, P | 1 |
| Kremastinos, DT | 2 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Stepacheva, TA | 1 |
| Ivannikova, OA | 1 |
| Pushnikova, EIu | 3 |
| Malakhovich, EV | 1 |
| Makushkin, EV | 1 |
| Zenevich, MV | 1 |
| Bourassa, MG | 1 |
| Abdelnoor, M | 2 |
| Müller, C | 1 |
| Lyle, PA | 3 |
| Edelman, JM | 1 |
| Snapinn, SM | 1 |
| Dimopoulos-Xicki, L | 1 |
| Haas, M | 1 |
| Sadionchenko, VS | 1 |
| Iakovleva, MS | 1 |
| Shekhian, GG | 1 |
| Mironova, MA | 1 |
| Redelmeier, D | 1 |
| Scales, D | 1 |
| Kopp, A | 1 |
| Füessl, HS | 1 |
| Kowey, PR | 1 |
| Kupfer, S | 2 |
| Kolloch, RE | 1 |
| Benetos, A | 2 |
| Coca, A | 1 |
| Cooper-DeHoff, RM | 1 |
| Handberg, E | 1 |
| Gaxiola, E | 1 |
| Conti, CR | 3 |
| Hewkin, AC | 2 |
| Tavazzi, L | 2 |
| Kaliuzhina, EV | 1 |
| Solovtsev, MA | 1 |
| Maleeva, MA | 2 |
| Fonarow, GC | 1 |
| Anis, AH | 1 |
| Sun, H | 1 |
| Singh, S | 1 |
| Woolcott, J | 1 |
| Nosyk, B | 1 |
| Brisson, M | 1 |
| Piller, LB | 1 |
| Cutler, JA | 1 |
| Furberg, C | 2 |
| Dunn, K | 1 |
| Franklin, S | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Proschan, M | 1 |
| Ellsworth, A | 1 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Kolloch, R | 1 |
| Chen, YF | 1 |
| Yang, YJ | 1 |
| Chen, X | 1 |
| Ruan, YM | 1 |
| Sun, RC | 1 |
| Tian, Y | 1 |
| Zhou, YW | 1 |
| Wang, QZ | 1 |
| Si, WX | 1 |
| Chen, JL | 1 |
| Gao, RL | 1 |
| Chen, ZJ | 1 |
| Rinfret, S | 1 |
| Abrahamowicz, M | 1 |
| Tu, J | 1 |
| Humphries, K | 1 |
| Eisenberg, MJ | 1 |
| Richard, H | 1 |
| Austin, PC | 1 |
| Pilote, L | 1 |
| Seljeflot, I | 1 |
| Arnesen, H | 1 |
| Hostmark, AT | 1 |
| Westheim, AS | 1 |
| Aursnes, I | 1 |
| Osnes, JB | 1 |
| Tvete, IF | 1 |
| Gåsemyr, J | 1 |
| Natvig, B | 1 |
| Rahn, KH | 1 |
| Gleim, GW | 1 |
| Kizer, JR | 1 |
| Lindgren, P | 1 |
| Buxton, M | 1 |
| Kahan, T | 1 |
| Poulter, NR | 2 |
| Sever, PS | 2 |
| Jönsson, B | 1 |
| Franco, V | 1 |
| Manhem, K | 1 |
| Beattie, WS | 1 |
| Wijeysundera, DN | 1 |
| Karkouti, K | 1 |
| McCluskey, S | 1 |
| Tait, G | 1 |
| Yusuf, S | 9 |
| Ramsdale, D | 6 |
| Peto, R | 4 |
| Furse, L | 3 |
| Bennett, D | 4 |
| Bray, C | 4 |
| Telford, AM | 1 |
| Wilson, C | 1 |
| Hampton, JR | 3 |
| Burmeister, WE | 1 |
| Reynolds, RD | 1 |
| Lee, RJ | 1 |
| Wilcox, RG | 3 |
| Ramsdale, DR | 1 |
| Faragher, EB | 1 |
| Bennett, DH | 1 |
| Bray, CL | 1 |
| Ward, C | 1 |
| Hjalmarson, A | 2 |
| Rossi, P | 6 |
| Jackson, EA | 1 |
| Sullman, SA | 1 |
| Johns, VJ | 1 |
| Frishman, WH | 1 |
| Furberg, CD | 1 |
| Friedewald, WT | 1 |
| Körst, HA | 1 |
| Brandes, JW | 1 |
| Lembcke, HJ | 1 |
| Littmann, KP | 1 |
| Rossi, PR | 1 |
| Furze, L | 2 |
| Pearson, M | 2 |
| Sterry, H | 2 |
| Parish, S | 2 |
| Bass, C | 1 |
| Webster, J | 1 |
| Petrie, JC | 1 |
| McLean, I | 1 |
| Hawksworth, GM | 1 |
| Banka, N | 1 |
| Anand, IS | 1 |
| Chakravarti, RN | 1 |
| Sharma, PL | 1 |
| Hausen, T | 1 |
| Robson, RH | 1 |
| Vishwanath, MC | 1 |
| Motwani, R | 1 |
| Gray, R | 1 |
| Struthers, AD | 1 |
| Reid, JL | 1 |
| Whitesmith, R | 1 |
| Rodger, JC | 1 |
| Roland, JM | 2 |
| Banks, DC | 2 |
| Mitchell, JR | 1 |
| May, GS | 1 |
| DeMets, DL | 1 |
| Friedman, LM | 1 |
| Passamani, E | 1 |
| McNeil, GN | 1 |
| Shaw, PK | 1 |
| Dock, DS | 1 |
| Chlup, J | 1 |
| Engel, HJ | 1 |
| Pretschner, P | 1 |
| Lichtlen, PR | 1 |
| Pimenta, J | 1 |
| Censoni, LG | 1 |
| Miranda, M | 1 |
| Mafrici, A | 1 |
| Mauri, F | 1 |
| Maggioni, AP | 1 |
| Franzosi, MG | 1 |
| Santoro, L | 2 |
| De Vita, C | 1 |
| Schulz, R | 1 |
| Rose, J | 1 |
| Skyschally, A | 1 |
| Heusch, G | 1 |
| Shimada, K | 1 |
| Nishikimi, T | 1 |
| Kawarabayashi, T | 1 |
| Takeuchi, K | 1 |
| Takeda, T | 1 |
| Söderlin, MK | 1 |
| Purhonen, S | 1 |
| Haring, P | 1 |
| Hietakorpi, S | 1 |
| Koski, E | 1 |
| Nuutinen, LS | 1 |
| Patel, J | 1 |
| Lee, W | 1 |
| Fusilli, L | 1 |
| Regan, TJ | 1 |
| Huang, MH | 1 |
| Schwartz, PJ | 1 |
| Hull, SS | 1 |
| Sandrone, G | 1 |
| Mortara, A | 1 |
| Torzillo, D | 1 |
| La Rovere, MT | 1 |
| Malliani, A | 1 |
| Lombardi, F | 1 |
| Kyriakides, ZS | 2 |
| Heidbüchel, H | 2 |
| Tack, J | 1 |
| Vanneste, L | 1 |
| Ballet, A | 1 |
| Ector, H | 1 |
| Van de Werf, F | 3 |
| Poucher, SM | 1 |
| Brooks, R | 1 |
| Pleeth, RM | 1 |
| Conant, AR | 1 |
| Collis, MG | 1 |
| Caramelli, B | 1 |
| dos Santos, RD | 1 |
| Abensur, H | 1 |
| Gebara, OC | 1 |
| Tranchesi, B | 1 |
| Bellotti, G | 1 |
| Pileggi, F | 1 |
| Kennedy, C | 1 |
| Janssens, L | 1 |
| Brzostek, T | 1 |
| Mortelmans, L | 1 |
| Wackers, FJ | 1 |
| Willems, GM | 1 |
| Lesaffre, E | 1 |
| Scheys, I | 1 |
| Collen, D | 1 |
| Santarelli, P | 1 |
| Lanza, GA | 1 |
| Biscione, F | 1 |
| Natale, A | 1 |
| Corsini, G | 1 |
| Riccio, C | 1 |
| Occhetta, E | 1 |
| Gronda, M | 1 |
| Makmur, J | 1 |
| Tuininga, YS | 1 |
| Crijns, HJ | 1 |
| Brouwer, J | 1 |
| van den Berg, MP | 1 |
| Man in't Veld, AJ | 1 |
| Mulder, G | 1 |
| Lie, KI | 1 |
| Franklin, BA | 1 |
| Gordon, S | 1 |
| Timmis, GC | 1 |
| Lezaun, R | 1 |
| Maraví, C | 1 |
| Gervás, H | 1 |
| Madariaga, I | 1 |
| Basterra, N | 1 |
| de los Arcos, E | 1 |
| Rayo Llerena, I | 1 |
| Marín Huerta, E | 1 |
| Burger, AJ | 1 |
| Kamalesh, M | 1 |
| Kumar, S | 1 |
| Nesto, R | 1 |
| Baldassarre, S | 1 |
| Unger, P | 1 |
| Renard, M | 1 |
| Bashour, TT | 1 |
| Espinosa, E | 1 |
| Blumenthal, J | 1 |
| Wong, T | 1 |
| Mason, DT | 1 |
| Killip, T | 1 |
| Davies, RF | 1 |
| Goldberg, AD | 1 |
| Forman, S | 1 |
| Knatterud, GL | 1 |
| Geller, N | 1 |
| Sopko, G | 1 |
| Pratt, C | 1 |
| Deanfield, J | 1 |
| de Meester, A | 1 |
| Chaudron, JM | 1 |
| de Roy, L | 1 |
| Rocha, P | 1 |
| Pathé, M | 1 |
| Bernaud, C | 1 |
| Zannier, D | 1 |
| Baron, B | 1 |
| Marchand, X | 1 |
| Hotton, JM | 1 |
| Kahn, JC | 1 |
| Casati, C | 1 |
| Forlani, A | 1 |
| Lozza, G | 1 |
| Monopoli, A | 1 |
| Goodman, S | 1 |
| Hill, C | 1 |
| Bata, I | 1 |
| Fung, A | 1 |
| Higginson, L | 1 |
| Lam, J | 1 |
| Massel, D | 1 |
| McCans, J | 1 |
| Nasmith, J | 1 |
| Stanton, E | 1 |
| Thompson, C | 1 |
| Warnica, W | 1 |
| Langer, A | 1 |
| Kostis, JB | 1 |
| Cutler, J | 1 |
| Grimm, RH | 2 |
| Berge, KG | 1 |
| Lacy, CR | 1 |
| Perry, HM | 1 |
| Blaufox, MD | 1 |
| Wassertheil-Smoller, S | 1 |
| Black, HR | 2 |
| Schron, E | 1 |
| Berkson, DM | 1 |
| Curb, JD | 1 |
| Smith, WM | 1 |
| McDonald, R | 1 |
| Applegate, WB | 1 |
| Lurje, L | 1 |
| Wennerblom, B | 1 |
| Tygesen, H | 1 |
| Karlsson, T | 1 |
| Puljevic, D | 1 |
| Smalcelj, A | 1 |
| Durakovic, Z | 1 |
| Goldner, V | 1 |
| Kardos, A | 1 |
| Long, V | 1 |
| Bryant, J | 1 |
| Singh, J | 1 |
| Casadei, B | 1 |
| Singh, JP | 1 |
| Musialek, P | 1 |
| Davey, P | 1 |
| Marinho, M | 1 |
| Hart, G | 1 |
| Wu, N | 1 |
| Fan, Z | 1 |
| Elliott, WJ | 1 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Grambsch, P | 1 |
| Hansson, L | 1 |
| Lacoucière, Y | 1 |
| Muller, J | 1 |
| Weber, MA | 1 |
| White, WB | 1 |
| Williams, G | 1 |
| Wittes, J | 1 |
| Zanchetti, A | 1 |
| Fakouhi, TD | 1 |
| Volpi, A | 1 |
| Cavalli, A | 1 |
| Negri, E | 1 |
| Pfisterer, M | 1 |
| Cox, JL | 1 |
| Granger, CB | 1 |
| Brener, SJ | 1 |
| Naylor, CD | 1 |
| Califf, RM | 1 |
| Stebbins, AL | 1 |
| Lee, KL | 1 |
| Topol, EJ | 1 |
| Nozawa, T | 1 |
| Inoue, H | 1 |
| Rochon, PA | 1 |
| Anderson, GM | 1 |
| Tu, JV | 1 |
| Gurwitz, JH | 1 |
| Clark, JP | 1 |
| Shear, NH | 1 |
| Lau, P | 1 |
| Zaugg, M | 1 |
| Tagliente, T | 1 |
| Lucchinetti, E | 1 |
| Jacobs, E | 1 |
| Krol, M | 1 |
| Bodian, C | 1 |
| Reich, DL | 1 |
| Silverstein, JH | 1 |
| Du, XJ | 1 |
| Cox, HS | 1 |
| Dart, AM | 1 |
| Esler, MD | 1 |
| Lipman, T | 1 |
| Heldal, M | 1 |
| Sire, S | 1 |
| Dale, J | 1 |
| Galcerá-Tomás, J | 1 |
| Castillo-Soria, FJ | 1 |
| Villegas-García, MM | 1 |
| Florenciano-Sánchez, R | 1 |
| Sánchez-Villanueva, JG | 1 |
| de La Rosa, JA | 1 |
| Martínez-Caballero, A | 1 |
| Valentí-Aldeguer, JA | 1 |
| Jara-Pérez, P | 1 |
| Párraga-Ramírez, M | 1 |
| López-Martínez, I | 1 |
| Iñigo-García, L | 1 |
| Picó-Aracil, F | 1 |
| Gottlieb, SS | 1 |
| McCarter, RJ | 1 |
| Mazur, NA | 1 |
| Vikent'ev, VV | 1 |
| Dickerson, LM | 1 |
| Carek, PJ | 1 |
| Wikstrand, J | 1 |
| Caulfield, M | 1 |
| Collins, R | 1 |
| McInnes, GT | 1 |
| Mehlsen, J | 1 |
| Nieminen, M | 1 |
| O'Brien, E | 1 |
| Ostergren, J | 1 |
| Clements-Jewery, H | 1 |
| Curtis, MJ | 1 |
| Ohte, N | 1 |
| Kurokawa, K | 1 |
| Iida, A | 1 |
| Narita, H | 1 |
| Akita, S | 1 |
| Yajima, K | 1 |
| Miyabe, H | 1 |
| Hayano, J | 1 |
| Kimura, G | 1 |
| Scheen, AJ | 1 |
| Boccalandro, F | 1 |
| Farias, J | 1 |
| Boccalandro, C | 1 |
| Vaisman, D | 1 |
| Stephan, K | 3 |
| Bischoff, KO | 2 |
| Geigenmüller, L | 2 |
| Diesch, J | 2 |
| Meesmann, W | 4 |
| Schley, G | 2 |
| Beckmann, R | 2 |
| Hengstebeck, W | 1 |
| Lopez, R | 1 |
| Edwards, B | 1 |
| Fentem, PH | 1 |
| Menken, U | 1 |
| Wiegand, V | 1 |
| Bucher, P | 1 |
| Langbehn, AF | 1 |
| Burmeister, G | 1 |
| Horst, H | 1 |
| Sonntag, F | 1 |
| Klempien, EJ | 1 |
| Frisch, P | 1 |
| Günnewig, H | 1 |
| Abendroth, RR | 1 |
| Hübner, H | 2 |
| Koudstaal, PJ | 1 |
| Algra, A | 1 |
| Pop, GA | 1 |
| Kappelle, LJ | 1 |
| van Latum, JC | 1 |
| van Gijn, J | 1 |
| Hauklien, H | 1 |
| Kremastinos, D | 1 |
| Karavolias, G | 1 |
| Papadopoulos, C | 1 |
| Apostolou, T | 1 |
| Paraskevaidis, J | 1 |
| Toutouzas, P | 1 |
| Green, BK | 1 |
| Gordon, GD | 1 |
| Horak, AR | 1 |
| Millar, RN | 1 |
| Commerford, PJ | 1 |
| Hochman, JS | 1 |
| Wong, SC | 1 |
| Held, P | 1 |
| Regårdh, CG | 1 |
| Swedberg, K | 1 |
| McAinsh, J | 1 |
| Herijgers, P | 1 |
| Flameng, W | 1 |
| Natale, E | 1 |
| Ricci, R | 1 |
| Tubaro, M | 1 |
| Milazzotto, F | 1 |
| Hervé, C | 1 |
| Castaigne, A | 1 |
| Vecchio, C | 1 |
| Chiarella, F | 1 |
| Lupi, G | 1 |
| Bellotti, P | 1 |
| Domenicucci, S | 1 |
| Khan, RM | 1 |
| Khan, TZ | 1 |
| Sud, P | 1 |
| Haq, G | 1 |
| Zafaruddin, M | 1 |
| Toft, E | 1 |
| Vyberg, M | 1 |
| Therkelsen, K | 1 |
| Cook, JR | 1 |
| Bigger, JT | 1 |
| Kleiger, RE | 1 |
| Fleiss, JL | 1 |
| Steinman, RC | 1 |
| Rolnitzky, LM | 1 |
| Cohn, PF | 1 |
| Cobbe, SM | 1 |
| Alexopoulos, D | 1 |
| Winner, SJ | 1 |
| McCaie, CP | 1 |
| Cobbe, PC | 1 |
| Johnston, J | 1 |
| Ren, XL | 3 |
| Lin, CX | 3 |
| Neil-Dwyer, G | 1 |
| Hayes, Y | 1 |
| Degaute, JP | 1 |
| Kuurne, T | 1 |
| Kytta, J | 1 |
| Carruthers, ME | 1 |
| Patel, S | 1 |
| Fletcher, GF | 1 |
| Erhardt, L | 1 |
| Wallentin, L | 1 |
| Wilhelmsen, L | 1 |
| Thorp, JM | 2 |
| Zacharias, FJ | 2 |
| Mazzuero, G | 1 |
| Galdangelo, F | 1 |
| Zotti, AM | 1 |
| Bertolotti, G | 1 |
| Meijer, A | 1 |
| Verheugt, FW | 1 |
| Mulcahy, D | 1 |
| Keegan, J | 1 |
| Cunningham, D | 1 |
| Quyyumi, A | 1 |
| Crean, P | 1 |
| Park, A | 1 |
| Wright, C | 1 |
| Fox, K | 1 |
| Keller, N | 1 |
| Sykulski, R | 1 |
| Thamsborg, G | 1 |
| Storm, T | 1 |
| Larsen, J | 1 |
| Pedersen, F | 1 |
| Madsen, JK | 1 |
| Grande, P | 1 |
| Sandøe, E | 1 |
| Jensen, H | 1 |
| Christiansen, P | 1 |
| Enk, B | 1 |
| Marcussen, H | 1 |
| Quedens, J | 1 |
| Hansen, J | 1 |
| Rynkiewicz, A | 1 |
| Midtbø, K | 1 |
| Silke, B | 1 |
| Verma, SP | 1 |
| Reynolds, GW | 1 |
| Hafizullah, M | 1 |
| Taylor, SH | 1 |
| Hamilton, I | 1 |
| Connacher, AA | 1 |
| Bouchier, IA | 1 |
| Pennert, K | 1 |
| Sörman, AE | 1 |
| Zacharias, FM | 1 |
| Grossman, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Hypertension in Hemodialysis Patients[NCT00582114] | Phase 3 | 200 participants (Actual) | Interventional | 2005-08-31 | Terminated (stopped due to Stopped by data safety monitoring board) | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris[NCT02547597] | Phase 4 | 99 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [NCT00000478] | Phase 3 | 0 participants | Interventional | 1990-11-30 | Completed | ||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| The Glooko Diabetes Mobile Monitoring and Management Advantage Study[NCT02974816] | 197 participants (Actual) | Interventional | 2017-05-15 | Completed | |||
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| Contribution of COMT Haplotypes in Propranolol Analgesic Efficacy for Treating Post-surgical Pain After Laparoscopic Hemicolectomy[NCT02511483] | Phase 2 | 10 participants (Actual) | Interventional | 2015-05-18 | Terminated (stopped due to Difficulty with recruitment) | ||
| The Ability of Several Short-term Measures of RR Variability to Predict Mortality After Myocardial Infarction[NCT00005235] | 715 participants (Actual) | Observational | 1988-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiovascular events were counted by subject and included the following: myocardial infarction (MI), stroke, hospitalization for congestive heart failure (CHF), hospitalized angina, arrhythmias, cardiac arrest, coronary revascularization and heart valve replacement. Adverse events reported are those during the course of 12 months of participation in the trial. All serious adverse events were adjudicated by R.A. and A.D.S. who were masked to the drug assignment at the time of adjudication. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. The cardiovascular event rate was calculated by treatment group assignment. Incidence rate ratio (IRR) by treatment was then determined along with the 95% confidence intervals (95% CIs). As a post hoc analysis, we also determined the narrower definition of cardiovascular events per group that included MI, stroke, CHF, or cardiovascular death. (NCT00582114)
Timeframe: 1 yr
| Intervention | events/100 patient-years (Number) | |||
|---|---|---|---|---|
| Incidence rate, cardiovasular events | Incidence rate, combined MI, stroke, CHF, CV death | Incidence rate, congest heart failure | Incidence rate, all-cause hospitalizations | |
| Atenolol | 24.6 | 13.5 | 6.2 | 89.9 |
| Lisinopril | 58 | 31 | 20.2 | 144.3 |
The primary outcome of the study was the average reduction in left ventricular mass indexed for body surface area from baseline to 1 year. A mixed model was used with left ventricular mass index (LVMI) as the outcome variable. Fixed effects were indicator variables for time, treatment and their interaction. Random effect was subject and statistical inference was made using the maximum likelihood estimator. No imputation was made for missing data. (NCT00582114)
Timeframe: Baseline, 6 months, 12 months
| Intervention | g/m^2 (Mean) | |
|---|---|---|
| LVMI Change from baseline, 6 months | LVMI Change from baseline, 12 months | |
| Atenolol | -8.4 | -21.5 |
| Lisinopril | -3.4 | -15.1 |
26 reviews available for atenolol and Cardiovascular Stroke
| Article | Year |
|---|---|
Beta-blockers for preventing stroke recurrence.
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Cause of Death; Humans; Ischemic Attack, Transient | 2013 |
[Perioperative cardiovascular evaluation and management for noncardiac surgery].
Topics: Adrenergic beta-Antagonists; Anesthesia; Atenolol; Bisoprolol; Fatty Acids, Monounsaturated; Fluvast | 2014 |
[What are the alternatives to betablockers in 2009?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzazepines; Cardiomyopathies; Heart Failur | 2008 |
Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Atenolol; Biomarkers; Carbazoles; Car | 2012 |
The evolving role of β-adrenergic receptor blockers in managing hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atenolol; Cardiac Output; Cardiovascular Dise | 2012 |
Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; E | 2013 |
Beta-blockers and diabetes: the bad guys come good.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bisoprolol; Coronary Disease; Diabet | 2002 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations.
Topics: Adrenergic beta-Antagonists; Algorithms; Atenolol; Carbazoles; Carvedilol; Humans; Myocardial Infarc | 2006 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials.
Topics: Adrenergic beta-Antagonists; Atenolol; Heart Diseases; Heart Rate; Humans; Monitoring, Intraoperativ | 2008 |
The use of beta blockers for the reduction of mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Alprenolol; Atenolol; Clinical Trials as Topic; Double-Blind Method; Fe | 1981 |
Beta blocking agents: current status in the prevention of sudden coronary death.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Alprenolol; Atenolol; Clinical Trials as Topic; Coronary D | 1982 |
Comparative review of beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Atenolol; Humans; Hypertension; | 1984 |
Beta-blocking drugs for arrhythmias, hypertension, and ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressur | 1984 |
The use of beta-adrenergic blocking drugs in patients with myocardial infarction.
Topics: Adrenergic beta-Antagonists; Alprenolol; Angina Pectoris; Atenolol; Clinical Trials as Topic; Humans | 1984 |
Type A behaviour: recent developments.
Topics: Amiloride; Atenolol; Behavior Therapy; Benzothiadiazines; Cognition; Coronary Disease; Diuretics; Dr | 1984 |
The randomized clinical trial: bias in analysis.
Topics: Acute Disease; Alprenolol; Atenolol; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Huma | 1981 |
Myocardial infarction in a parturient. A case report with emphasis on medication and management.
Topics: Adult; Aspirin; Atenolol; Delivery, Obstetric; Drug Therapy, Combination; Female; Humans; Myocardial | 1994 |
Myocardial infarction in association with misuse of anabolic steroids.
Topics: Adult; Anabolic Agents; Aspirin; Atenolol; Doping in Sports; Echocardiography; Electrocardiography; | 1993 |
[Silent myocardial ischemia. Arguments in favor of treatment].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Atenolol; Calcium Channel Blockers; | 1996 |
[Silent myocardial ischemia. Arguments against treatment].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Atenolol; Bisoprolol; Calcium Channe | 1996 |
[Treatment with beta-blockers in patients with acute coronary syndrome].
Topics: Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Atenolol; Clinical Trials as Topic; Co | 1998 |
Primary prevention with beta-blockade in patients with hypertension: review of results and clinical implications.
Topics: Adrenergic beta-Antagonists; Atenolol; Benzothiadiazines; Clinical Trials as Topic; Data Interpretat | 1990 |
Atenolol and ischaemic heart disease: an overview.
Topics: Atenolol; Cause of Death; Circadian Rhythm; Clinical Trials as Topic; Coronary Disease; Humans; Myoc | 1991 |
Use of beta adrenoceptor blockade during and after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atenolol; Cardiotonic Agents; Clinical Trials as | 1986 |
94 trials available for atenolol and Cardiovascular Stroke
| Article | Year |
|---|---|
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Early Termination of Clinical T | 2014 |
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; De | 2014 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2015 |
Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angina, Stable; Atenolol; Carbazoles; Cardiotonic Agen | 2016 |
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Atenol | 2008 |
Influence of atenolol on coronary artery spasm after acute myocardial infarction in a Japanese population.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Asian People; Atenolol; Cohort St | 2010 |
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Coronary Disease; | 2009 |
In-treatment stroke volume predicts cardiovascular risk in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follo | 2011 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
[Effect of atenolol and trimetazidine on dispersion of cardiac rhythm in patients with moderately expressed postinfarction left ventricular dysfunction].
Topics: Anti-Arrhythmia Agents; Atenolol; Humans; Myocardial Infarction; Trimetazidine; Vasodilator Agents; | 2002 |
Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction.
Topics: Adrenergic alpha-Antagonists; Atenolol; Blood Glucose; Blood Pressure; Blood Viscosity; Carbazoles; | 2002 |
[Reduction of cardiovascular events with lorsartan? The LIFE Study].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cerebral Infarction; Doub | 2003 |
[The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiovascular Agents; Drug Therapy, Combination; Humans; Mal | 2003 |
Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Atenolol; C | 2004 |
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Atenolol; Female; Humans; Hypert | 2004 |
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hyp | 2004 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; | 2004 |
[Antihypertensive and antiischemic effectiveness and safety of the AT1-receptor blocker irbesartranin arterial hypertension in patients with prior myocardial infarction].
Topics: Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2004 |
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; | 2004 |
A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Carbazoles; Carvedilol; Female; Gated Blood-Pool Imagin | 2005 |
[Carvedilol in combined therapy of patients with Q myocardial infarction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atenolol; Carbazoles; Carvedilol; Drug | 2005 |
[Quality of life of patients with old myocardial infarction on prolonged therapy with atenolol].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Drug Administration Schedule; Female; Hemodynamics; Hu | 2006 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cause of Death; Coronary Artery Disease; Di | 2006 |
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients.
Topics: Antioxidants; Atenolol; Carbazoles; Carvedilol; Female; Humans; Long-Term Care; Male; Middle Aged; M | 2007 |
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Compli | 2007 |
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus | 2008 |
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Female; | 2008 |
Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial.
Topics: Acute Disease; Atenolol; Clinical Enzyme Tests; Clinical Trials as Topic; Electrocardiography; Femal | 1980 |
Beta-blockers in immediate treatment of myocardial infarction.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Clinical Trials as Topic; Humans; Myoca | 1980 |
Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome.
Topics: Atenolol; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Drug Therapy, Combination | 1981 |
The use of beta blockers for the reduction of mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Alprenolol; Atenolol; Clinical Trials as Topic; Double-Blind Method; Fe | 1981 |
Acute intervention studies in patients with myocardial infarction using atenolol, propranolol, oxprenolol and disopyramide phosphate.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Disopyramide; Double-B | 1981 |
Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Coronary Disease; Double-Blind Method; Female | 1982 |
Beta blocking agents: current status in the prevention of sudden coronary death.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Alprenolol; Atenolol; Clinical Trials as Topic; Coronary D | 1982 |
Beta-blockade in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Clinical Trials as Topic; Creatine Kinase; Elect | 1982 |
The use of beta-adrenergic blocking drugs in patients with myocardial infarction.
Topics: Adrenergic beta-Antagonists; Alprenolol; Angina Pectoris; Atenolol; Clinical Trials as Topic; Humans | 1984 |
[Atenolol in the treatment of premature ventricular contractions. A double blind study in 68 patients (author's transl)].
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiac Complexes, Premature; Coronary Disease; Double-Blind | 1981 |
Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiac Complexes, Premature; Clinical Trials as Topic; | 1983 |
The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction.
Topics: Arrhythmias, Cardiac; Atenolol; Clinical Trials as Topic; Creatine Kinase; Electrocardiography; Fema | 1984 |
Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction.
Topics: Administration, Oral; Atenolol; Electrocardiography; Female; Heart Diseases; Humans; Male; Middle Ag | 1983 |
The effects of cardioselective and non-selective beta-adrenoceptor blockade on the hypokalaemic and cardiovascular responses to adrenomedullary hormones in man.
Topics: Adult; Atenolol; Blood Pressure; Epinephrine; Heart Rate; Humans; Hypokalemia; Male; Myocardial Infa | 1983 |
Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Depression, Chemical; Double-Blind | 1980 |
The randomized clinical trial: bias in analysis.
Topics: Acute Disease; Alprenolol; Atenolol; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Huma | 1981 |
Early intravenous atenolol treatment in suspected acute myocardial infarction.
Topics: Atenolol; Clinical Trials as Topic; Creatine Kinase; Electrocardiography; Heart Rate; Humans; Inject | 1981 |
[Atenolol i.v. in the acute phase of AMI: the indications, contraindications and interactions with thrombolytic drugs in the GISSI-2 study. The GISSI-2 Researchers. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].
Topics: Aged; Atenolol; Cause of Death; Chi-Square Distribution; Contraindications; Drug Interactions; Drug | 1995 |
Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Clonidine; Double-Blind Method; Electrocardi | 1994 |
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiovascular Agents; Clonidine; Double-Blind Method; | 1993 |
Effects of thrombolysis and atenolol or metoprolol on the signal-averaged electrocardiogram after acute myocardial infarction. Late Potentials Italian Study (LAPIS).
Topics: Aged; Atenolol; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; I | 1993 |
Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group.
Topics: Aged; Atenolol; Blood Pressure; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transien | 1993 |
Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Atenolol; Autonomic Nervous System; Circadi | 1995 |
Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Autonomic Nervous System; Betaxolol; Electro | 1996 |
Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Atenolol; Calcium Channel Blocker | 1997 |
Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol.
Topics: Acute Disease; Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Female; H | 1997 |
PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Calcium Channel Blockers; Death, Sudden, Cardiac; Dilt | 1996 |
Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Double-Blind Method; Electrocard | 1997 |
Heart rate variability after acute myocardial infarction in patients treated with atenolol and metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Autonomic Nervous System; Cross-Over Studies; De | 1997 |
The influence of atenolol and propafenone on QT interval dispersion in patients 3 months after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Atenolol; Electrocardiography; Female; Follow-Up Studies; Humans; Male; | 1997 |
Lipophilic versus hydrophilic beta(1) blockers and the cardiac sympatho-vagal balance during stress and daily activity in patients after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Baroreflex; Cross-Over Studies; Double-Blind Met | 1998 |
Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. Beijing Collaborative Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Cardiac Outpu | 1997 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double- | 1998 |
Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atenolol; Drug Administration Routes; Electrocardio | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1998 |
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Atenolol; Cause of Death; Dose-Response Rel | 1998 |
Pre-hospital treatment of patients with suspected acute myocardial using a beta-blocking agent: a double-blind feasibility study. EMIP-BB Pilot Study Group.
Topics: Atenolol; Double-Blind Method; Emergency Medical Services; Feasibility Studies; Female; Follow-Up St | 1994 |
Beneficial effects from beta-adrenergic blockade in elderly patients undergoing noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Algorithms; Atenolol; Blood Pressure; Cardiova | 1999 |
Randomised training after myocardial infarction: short and long-term effects of exercise training after myocardial infarction in patients on beta-blocker treatment. A randomized, controlled study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Electrocardiography; Exercise Test; Exercise Therapy; F | 2000 |
Effects of early use of atenolol or captopril on infarct size and ventricular volume: A double-blind comparison in patients with anterior acute myocardial infarction.
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Bloo | 2001 |
[Postinfarction remodeling of the left atrium and left ventricle: effects of long-term treatment with beta adrenergic blockers and angiotensin converting enzyme inhibitors].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Atrial Funct | 2001 |
Frequency of postprandial lipemia after a first acute coronary event (unstable angina pectoris or non-ST-segment elevation acute myocardial infarction) and the effects of atenolol on the lipemia.
Topics: Angina, Unstable; Area Under Curve; Atenolol; Cholesterol; Fasting; Female; Humans; Hyperlipidemias; | 2002 |
Anti-dysrhythmic treatment in acute myocardial infarction.
Topics: Acute Disease; Administration, Oral; Atenolol; Clinical Trials as Topic; Disopyramide; Double-Blind | 1979 |
Effect of atenolol on recovery of the electrocardiographic signs of myocardial infarction.
Topics: Acute Disease; Aged; Atenolol; Clinical Trials as Topic; Electrocardiography; Follow-Up Studies; Hea | 1979 |
Effect of beta-blockers on arrhythmias during six weeks after suspected myocardial infarction.
Topics: Arrhythmias, Cardiac; Atenolol; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; | 1979 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
[Pharmacological effects on left diastolic ventricular function in acute myocardial infarct: comparison of gallopamil and atenolol].
Topics: Adult; Aged; Atenolol; Coronary Care Units; Diastole; Double-Blind Method; Echocardiography, Doppler | 1991 |
Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study.
Topics: Adult; Aged; Aspirin; Atenolol; Embolism; Female; Fibrinolytic Agents; Heart; Heart Diseases; Heart | 1991 |
Effect of atenolol and diltiazem on heart period variability in normal persons.
Topics: Adult; Atenolol; Diltiazem; Electrocardiography, Ambulatory; Female; Heart; Humans; Male; Myocardial | 1991 |
A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiac Complexes, Premature; Clinical Trials as Topic; | 1988 |
Stress/catecholamine-induced cardiac necrosis. Reduction by beta 1-selective blockade.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Child; Clinical Trials as Topic; Craniocere | 1988 |
Use of beta adrenoceptor blockade during and after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atenolol; Cardiotonic Agents; Clinical Trials as | 1986 |
Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.
Topics: Administration, Oral; Age Factors; Aged; Atenolol; Cardiotonic Agents; Clinical Trials as Topic; Dru | 1986 |
Intravenous beta-blockade during acute myocardial infarction.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Clinical Trials as Topic; Humans; Injec | 1986 |
[2 international multicenter studies. Early treatment with beta blockaders in acute chest pain reduces the risk of definitive development of myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Chest Pain; Clinical Trials as Topic; Humans; Metoprolo | 1987 |
Effects of propranolol, atenolol, and chlordesmethyldiazepam on response to mental stress in patients with recent myocardial infarction.
Topics: Adult; Aged; Anti-Anxiety Agents; Atenolol; Benzodiazepines; Diazepam; Electrocardiography; Hemodyna | 1987 |
Beta blockade early in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Atenolol; Clinical Trials as Topic; Follow-Up Studies; Humans; Myocardi | 1987 |
Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group.
Topics: Atenolol; Clinical Trials as Topic; Coronary Disease; Heart Rupture; Humans; Ireland; Myocardial Inf | 1988 |
Circadian variation of total ischaemic burden and its alteration with anti-anginal agents.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Circadian Rhythm; Clinical Trials as Topic; Coronary Disease | 1988 |
Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol.
Topics: Acebutolol; Aged; Atenolol; Atrial Natriuretic Factor; Clinical Trials as Topic; Coronary Disease; E | 1988 |
[Atenolol in suspected acute myocardial infarction. The Danish experience of participation in an international multi-center study].
Topics: Atenolol; Clinical Trials as Topic; Denmark; Humans; International Cooperation; Multicenter Studies | 1988 |
[Effect of atenolol on the QT interval in the acute phase of myocardial infarction].
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Clinical Trials as Topic; Female; Humans; Long QT Syndr | 1988 |
Circulatory effects of intravenous and oral atenolol in acute myocardial infarction.
Topics: Administration, Oral; Atenolol; Dose-Response Relationship, Drug; Hemodynamics; Humans; Injections, | 1988 |
Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pr | 1987 |
97 other studies available for atenolol and Cardiovascular Stroke
| Article | Year |
|---|---|
Development of Robust 17(
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arachidonic Acids; Dose-Response Relationship | 2019 |
The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Female; Gout; H | 2020 |
Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Humans; Inflammation; Metoprolol; Mice; Myocardial I | 2020 |
It takes the right medications to prevent a million heart attacks and strokes.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Health Promoti | 2014 |
Mortality and reinfarction among patients using different beta-blockers for secondary prevention after a myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Bisoprolol; Female; Humans; Kaplan-Meier Estimate; Male | 2009 |
Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Animals; Atenolol; Benzazepines; Bradykinin; Cardiotoni | 2009 |
Left ventricular remodeling after myocardial infarction: characterization of a swine model on beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Disease Models, Animal; Echocardiography; Heart Vent | 2009 |
β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blotting, Northern; Ca(2+) Mg(2+)-ATPase; Dose-Respo | 2011 |
Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Benzazepines; Bradycardia; Cell Survival; Cicatrix; Coron | 2010 |
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Follow-Up S | 2011 |
What your blood pressure isn't revealing.
Topics: Adrenergic beta-Antagonists; American Heart Association; Amlodipine; Anti-Arrhythmia Agents; Antihyp | 2010 |
Reduction of postoperative mortality: pattern of use of β-blockade, bias, or both?
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Bias; Dose-Response Relationship, Drug; Female; Humans; | 2011 |
Perioperative β-blockade protocol unproven.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Dose-Response Relationship, Drug; Female; Humans; Kapla | 2011 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Ca | 2003 |
[Ischemic heart disease in patients with arteriopathies].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Antihypertensive Agents; Arterioscle | 2002 |
The LIFE study: the straw that should break the camel's back.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; My | 2003 |
Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Atenolol; Dogs; Dose-Response Relationship, Dru | 2003 |
[Effects of monotherapy with an alpha1-adrenoblocker doxazosin and its combination with beta1-adrenoblocker atenolol on hemodynamics, reversible myocardial ischemia in postmyocardial infarction patients with arterial hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; | 2003 |
Intravenous atenolol and esmolol maintain the protective effect of ischemic preconditioning in vivo.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Hemodynamics; Infusions, Intravenous; Ischemic Preco | 2004 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Reduction of heart rate by chronic beta1-adrenoceptor blockade promotes growth of arterioles and preserves coronary perfusion reserve in postinfarcted heart.
Topics: Adrenergic beta-Antagonists; Animals; Arterioles; Atenolol; Cardiac Output; Clonidine; Coronary Vess | 2005 |
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2005 |
[Therapeutic implications of ACE-gene polymorphism].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Canada; Elective Surgical Procedures; Female; Hospital | 2005 |
[Antihypertensive therapy: campaign of the giants].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; D | 2005 |
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium | 2006 |
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cohort Studies | 2006 |
[Effects of atenolol and metoprolol on cardiomyocyte apoptosis and related gene expression after acute myocardial infarction in rats].
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Atenolol; bcl-2-Associated X Protein; Female; Metop | 2006 |
[Dilemma of antihypertensive therapy: high blood pressure diminishes, potency sometimes, too].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2006 |
A population-based analysis of the class effect of beta-blockers after myocardial infarction.
Topics: Acebutolol; Adrenergic beta-Antagonists; Aged; Atenolol; Female; Humans; Male; Metoprolol; Myocardia | 2007 |
Does atenolol differ from other beta-adrenergic blockers?
Topics: Adrenergic beta-Antagonists; Atenolol; Bayes Theorem; Humans; Hypertension; Meta-Analysis as Topic; | 2007 |
[Treating essential hypertension. Are beta blockers still first choice?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cor | 2007 |
Atenolol, heparin and the intermediate coronary syndrome.
Topics: Administration, Oral; Atenolol; Heparin; Humans; Methods; Myocardial Infarction; Propanolamines | 1981 |
Limitation of myocardial infarct size by atenolol, nadolol and propranolol in dogs.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Dogs; Female; Heart; Heart Rate; Mal | 1981 |
Early intravenous beta-blockade in myocardial infarction.
Topics: Adrenergic beta-Antagonists; Atenolol; Creatine Kinase; Electrocardiography; Heart Rate; Humans; Inj | 1982 |
Flurbiprofen interaction with single doses of atenolol and propranolol.
Topics: Adult; Aldosterone; Atenolol; Blood Pressure; Body Weight; Female; Flurbiprofen; Heart Rate; Humans; | 1984 |
Effect of atenolol, nifedipine & oxyfedrine on experimental myocardial infarct size in rhesus monkeys.
Topics: Animals; Atenolol; Blood Pressure; Heart Rate; Macaca mulatta; Myocardial Infarction; Nifedipine; Ox | 1984 |
[Withdrawal syndrome following beta blocker therapy (author's transl)].
Topics: Adult; Angina Pectoris; Atenolol; Chlorthalidone; Female; Humans; Hypertension; Middle Aged; Myocard | 1981 |
Nifedipine and beta-blockade as a cause of cardiac failure.
Topics: Atenolol; Drug Therapy, Combination; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction | 1982 |
Substitution of atenolol for propranolol in a case of propranolol-related depression.
Topics: Angina Pectoris; Atenolol; Depressive Disorder; Female; Humans; Hypertension; Imipramine; Middle Age | 1982 |
[201-thallium stress scintigram in patients with coronary artery disease after administration of the cardioselective betablocker atenolol (author's transl)].
Topics: Adult; Angina Pectoris; Atenolol; Coronary Circulation; Coronary Disease; Humans; Male; Middle Aged; | 1981 |
[Effect of atenolol on ST segment elevation during acute phase of transmural myocardial infarction of the anterior wall].
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Electrocardiography; Female; Hemodynamics; Humans; Male | 1980 |
What happened to intravenous atenolol in acute myocardial infarction?
Topics: Atenolol; Humans; Infusions, Intravenous; Myocardial Infarction; Practice Patterns, Physicians'; Ran | 1994 |
Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol.
Topics: Adenosine Triphosphate; Animals; Atenolol; Benzazepines; Blood Pressure; Bradycardia; Cardiovascular | 1995 |
Effect of prolonged beta-adrenergic blockade induced by atenolol on left ventricular remodeling after acute myocardial infarction in the rat.
Topics: Animals; Atenolol; Heart Rate; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Myocardiu | 1995 |
Anti-arrhythmic efficacy of beta-adrenergic blockade during acute ischemia in myocardium with scar.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Disease Models, Animal; Dogs; Heart | 1994 |
Unexpected interaction between beta-adrenergic blockade and heart rate variability before and after myocardial infarction. A longitudinal study in dogs at high and low risk for sudden death.
Topics: Animals; Atenolol; Autonomic Nervous System; Death, Sudden, Cardiac; Dogs; Heart; Heart Rate; Longit | 1994 |
Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction.
Topics: Atenolol; Circadian Rhythm; Echocardiography; Electrocardiography, Ambulatory; Exercise Test; Heart | 1994 |
Safety of beta-adrenergic blockade in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Humans; Myocardial Infarction | 1993 |
Myocardial infarction and purine transport inhibition in anaesthetised ferrets.
Topics: Adenosine; Animals; Atenolol; Blood Gas Analysis; Blood Pressure; Coronary Circulation; Ferrets; Hea | 1994 |
Beta-blocker infusion did not improve left ventricular diastolic function in myocardial infarction: a Doppler echocardiography and cardiac catheterization study.
Topics: Adult; Atenolol; Cardiac Catheterization; Diastole; Echocardiography, Doppler; Female; Hemodynamics; | 1993 |
Diurnal variation of ischemic response to exercise in patients receiving a once-daily dose of beta-blockers. Implications for exercise testing and prescription of exercise and training heart rates.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Atenolol; Blood Pressure; Circadian Rhy | 1996 |
Acute myocardial infarction and myocardial bridging: a case report.
Topics: Anistreplase; Atenolol; Coronary Angiography; Coronary Vessel Anomalies; Electrocardiography; Follow | 1996 |
Myocardial infarction caused by coronary artery myocardial bridge.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Atenolol; Cardiac Catheterization; Coronary Angio | 1997 |
Silent myocardial ischemia: some good news.
Topics: Adrenergic beta-Antagonists; Atenolol; Calcium Channel Blockers; Combined Modality Therapy; Coronary | 1997 |
Usefulness of isoproterenol in the induction of clinical sustained ventricular tachycardia during electrophysiological study.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Atenolol; Cardiac Pacing, Artificial; E | 1997 |
Hemodynamic changes do not mediate the cardioprotection induced by the A1, adenosine receptor agonist CCPA in the rabbit.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Analysis of Variance; Animals; Antihypertensive Agents | 1997 |
Effect of atenolol or metoprolol on waking hour dynamics of the QT interval in myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Case-Control Studies; Circadian Rhythm; Electroc | 1998 |
Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Atenolol; Chlorthalidone; Confide | 1999 |
Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Atenolol; | 1999 |
beta Blockade after myocardial infarction. Absence of evidence is failure of research policy.
Topics: Adrenergic beta-Antagonists; Atenolol; Clinical Trials as Topic; Humans; Myocardial Infarction; Odds | 2000 |
[Depression of diurnal dispersion of sinus rhythm in patients after myocardial infarct].
Topics: Adult; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Circadian Rhythm; Da | 2000 |
Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Baltimore; Female; Humans; Male; Medical Records; Metop | 2001 |
Are all beta-blockers equally effective in reducing mortality after acute myocardial infarction (AMI)?
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Drug Costs; Evidence-Based Medicine; Female; Humans; Ma | 2001 |
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Benzothiadiazines; Coronary Disease; Diuretics; Human | 2001 |
Modulation of ventricular arrhythmias by catecholamines during evolving infarction in the isolated perfused rat heart.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Catecholamines; Coronary Circulation; Electrocardiog | 2001 |
Myocardial oxidative metabolism in remote normal regions in the left ventricles with remodeling after myocardial infarction: effect of beta-adrenoceptor blockers.
Topics: Acetates; Adrenergic beta-Antagonists; Atenolol; Carbon Radioisotopes; Cardiac Catheterization; Case | 2002 |
[Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Endpoint Determination; Female; H | 2002 |
[Effect of a new beta-sympatholytic agent for ICI 66 082 on hemodynamics and cardiac contraction without and with experimental coronary occlusion].
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Dogs; Hemodynamics; Myocardial Contraction; Myocardi | 1975 |
[The treatment of acute cardiac dysrhythmias with atenolol (Tenormin) particularly after myocardial infarction (author's transl)].
Topics: Acute Disease; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Atrial Flutter; Car | 1978 |
Prophylaxis of ventricular fibrillation after acute experimental coronary occlusion by chronic beta-adrenoceptor blockade with atenolol.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Dogs; Drug Administration Schedule; Heart Rate; Isoproteren | 1979 |
[Long term effects of the beta-adrenergic blocking agent atenolol (Tenormin) on coronary heart disease: a study of 125 patients (author's transl)].
Topics: Adult; Aged; Atenolol; Blood Pressure; Coronary Disease; Drug Evaluation; Exercise Test; Female; Hea | 1978 |
[The effects of atenolol on the heart size, on the heart rate, and on the blood pressure at rest (author's transl)].
Topics: Atenolol; Blood Pressure; Heart; Heart Rate; Humans; Myocardial Infarction; Propanolamines; Pulse | 1978 |
[Management of acute arrhythmias using atenolol in the myocardial-infarct patient].
Topics: Aged; Arrhythmias, Cardiac; Atenolol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prop | 1978 |
[Prevention of arrhythmias in acute myocardial infarct using the beta-sympatholytic ICI 66082].
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Atenolol; Dogs; Myocardial Infarction; Propanolamines | 1976 |
[The effect of atenolol on contractility and hemodynamics of the infarcted heart in comparison to propranolol and practolol (author's transl)].
Topics: Animals; Atenolol; Blood Pressure; Cardiac Output; Coronary Circulation; Dogs; Dose-Response Relatio | 1975 |
[Treatment of hypertension in the elderly--diuretics/atenolol?].
Topics: Aged; Atenolol; Diuretics; Humans; Hypertension; Myocardial Infarction | 1992 |
Intravenous atenolol in elderly patients in the early phase of acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aging; Atenolol; Cardiac Output; Hemodynamics; Humans; Injections, I | 1992 |
Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction.
Topics: Administration, Oral; Adult; Aspirin; Atenolol; Combined Modality Therapy; Female; Humans; Infusions | 1992 |
Effect of atenolol on myocardial infarct expansion in a nonreperfused rat model.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Female; Heart Rate; Myocardial Infarction; Pilot Pro | 1991 |
Pharmacokinetic and pharmacodynamic properties of atenolol in acute myocardial infarction.
Topics: Adult; Aged; Atenolol; Blood Pressure; Female; Half-Life; Heart Rate; Humans; Male; Middle Aged; Myo | 1990 |
Coronary artery thrombosis and thrombolysis in baboons: the effect of atenolol treatment on myocardial infarct size.
Topics: Animals; Atenolol; Blood Pressure; Coronary Circulation; Coronary Thrombosis; Electrocardiography; F | 1991 |
[Thrombolysis for myocardial infarction before hospitalization].
Topics: Atenolol; Drug Therapy, Combination; Emergency Medical Services; Hospitalization; Humans; Myocardial | 1991 |
Intraoperative myocardial ischaemia in surgical patients with treated ischaemic heart disease.
Topics: Atenolol; Blood Pressure; Coronary Disease; Electrocardiography; Female; Humans; Intraoperative Comp | 1991 |
Diltiazem-induced granulomatous hepatitis.
Topics: Aged; Aspirin; Atenolol; Chemical and Drug Induced Liver Injury; Diltiazem; Female; Granuloma; Human | 1991 |
Silent myocardial ischemia--classification and management.
Topics: Angina Pectoris; Atenolol; Drug Therapy, Combination; Heart Function Tests; Hemodynamics; Humans; Hy | 1990 |
Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol).
Topics: Atenolol; Blood Pressure; Cerebrovascular Disorders; Electrocardiography; Female; Humans; Hypertensi | 1990 |
[The electrophysiologic effect of atenolol and nitrendipine on normal and ischemic rabbit myocardium in situ. II. Effects on effective refractory periods and its dispersion].
Topics: Action Potentials; Animals; Atenolol; Female; Heart; Male; Myocardial Infarction; Nitrendipine; Rabb | 1989 |
[The electrophysiologic effect of atenolol and nitrendipine on normal and ischemic rabbit myocardium in situ. I. Effects on transmembrane potential].
Topics: Action Potentials; Animals; Atenolol; Female; Heart; Male; Myocardial Infarction; Nitrendipine; Rabb | 1989 |
[The electrophysiologic effect of atenolol and nitrendipine on normal and ischemic rabbit myocardium in situ. III. Effects on ventricular fibrillation threshold].
Topics: Animals; Atenolol; Electric Stimulation; Electrophysiology; Female; Male; Myocardial Infarction; Nit | 1989 |
Exercise training during chronic beta blockade in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Coronary Artery Bypass; Female; Heart Rate; Humans; Male; Met | 1985 |
Benefits and potential harm of lowering high blood pressure.
Topics: Adolescent; Adult; Age Factors; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1987 |
Streptokinase plus beta-blockade after myocardial infarction.
Topics: Adult; Aged; Atenolol; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infa | 1988 |
Beta blockers, lipids, and coronary atherosclerosis.
Topics: Adult; Aged; Atenolol; Female; Humans; Lipids; Male; Middle Aged; Myocardial Infarction | 1988 |
Beta-blockade after myocardial infarction: is prolonged treatment feasible?
Topics: Adult; Aged; Atenolol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Propranolol; Time F | 1987 |
Beta blockade in early myocardial infarction.
Topics: Age Factors; Aged; Atenolol; Humans; Middle Aged; Myocardial Infarction; Time Factors | 1987 |